{
    "nctId": "NCT05960201",
    "briefTitle": "Diagnostic Performance of [18F]FES PET/CT for Axillary LN Metastasis in Invasive Lobular Carcinoma",
    "officialTitle": "A Phase 2, Open-label, Non-randomized, Single-center Study to Explore the Diagnostic Performance of [18F]FES PET/CT for the Assessment of Axillary Lymph Node Metastasis in Invasive Lobular Carcinoma of the Breast",
    "overallStatus": "COMPLETED",
    "conditions": "Carcinoma, Lobular",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "DIAGNOSTIC",
    "enrollmentCount": 23,
    "primaryOutcomeMeasure": "Patient based sensitivity, specificity, positive predictive and negative predictive values of a qualitative [18F]FES PET/CT assessment of axillary lymph node metastasis",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Male or female subjects aged 19 years or older regardless of race/ethnicity.\n* Subjects with histologically confirmed estrogen receptor-positive invasive lobular breast cancer within 90 days prior to \\[18F\\]FES PET/CT imaging\n* Subjects whose primary tumor of cT1-3 according to the American Joint Committee on Cancer (AJCC) 8th tumor staging system\n* Subjects with suspected or confirmed axillary lymph node metastasis clinically or in imaging test (ultrasound)\n* Subjects who scheduled to undergo sentinel node biopsy or axillay lymph node dissection within 90 days of \\[18F\\]FES PET/CT imaging\n* Subjects whose Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 2 points or less\n\nExclusion Criteria:\n\n* Subject or the subject's legally acceptable representative does not provide written informed consent form\n* Subjects with confirmed or suspected large, bulky, matted cN2 or cN3 axillary lymph node metastases, or distant metastases.\n* Previous history of ipsilateral axillary lymph node dissection, sentinel lymph node surgery, or lymph node dissection biopsy.\n* Patients who are scheduled for or have undergone chemotherapy, radiotherapy, antihormone therapy, targeted therapy, or immunotherapy between \\[18F\\]FES PET/CT and pathological diagnosis\n* Subjects who are pregnant or lactating. Exclusion of the possibility of pregnancy is made by one of the following: 1) Physiologically menopausal (menstruation has stopped for more than 2 years), 2) Surgically infertility (with a history of bilateral oophorectomy or hysterectomy), 3) In the case of subjects with a possibility of pregnancy, negative serum or urine pregnancy test before administration of \\[18F\\]FES has to be negative within 24 hours, and the subjects are instructed to use contraception during her participation in this study.\n* Subject has concurrent severe and/or uncontrolled and/or unstable medical condition other than cancer (e.g., congestive heart failure, acute myocardial infarction, severe lung disease, chronic kidney disease or chronic liver disease).\n* Subject is a relative or student of the investigator or otherwise in a dependent relationship\n* Subject has already participated in this study\n* Subject not being able to provide intact data for this study due to personal circumstances or other reasons in the judgment of the investigator",
    "sex": "ALL",
    "minimumAge": "19 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}